ANI Pharmaceuticals to Report Q4 & Full Year 2025 Results – Feb 27, 2026

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) will release its fourth quarter and full year 2025 financial results on February 27, 2026, before the market opens, the company announced Friday.

The company plans to hold a conference call at 8:00 a.m. Eastern Time that day to discuss the results. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, are scheduled to participate, according to a statement released by ANI Pharmaceuticals.

Investors can access the call toll-free at 800-274-8461, using conference ID 5230834. A live webcast and archived replay will be available on the company’s website, www.anipharmaceuticals.com, under the “Investors” section.

ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing therapeutics. The company’s business segments include Rare Disease, Generics, and Brands, with a focus on areas like ophthalmology, rheumatology, nephrology, neurology, and pulmonology.

The announcement follows a period of growth for the company, as it continues to expand its portfolio of both novel and generic products, according to recent reports. The company’s Rare Disease business has been a key driver of growth, with a focus on innovative treatments for underserved patient populations.

Courtney Mogerley of Argot Partners is the investor relations contact for ANI Pharmaceuticals, and can be reached at [email protected] or 646-368-8014.